44 results about "Fixed-dose combination" patented technology

The present application discloses combinations for treating estrogen receptor-positive and HER2-positive breast cancer patients. The combinations comprise pertuzumab and trastuzumab (e.g. a fixed dose combination of pertuzumab and trastuzumab, PH FDC) plus giredestrant. In one embodiment, the combination further includes a CDK4 / 6 inhibitor, such as abemaciclib or palbociclib.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

The invention includes dry powder nintedanib formulation for dispersion and inhalation administration including salts thereof, indolinone derivative or salts thereof and in fixed dose combinations with carrier agents and other active ingredients. The aerosol delivery combination formulation may be administered as an inhaled aerosol over a few actuations or by two or more actuations. Each dose may be administered one or more times daily on a regular or interval daily dosing regimen. The special formulation parameters of the invention include the selection of the salt for complexation with the form of nintedanib used for an isolated dry powder along with particle size distributions and combination with a force control agent for improved aerosol delivery. Methods of the invention include therapeutically effective doses of the described invention used to treat interstitial lung disease.

The present invention includes dry powder nintedanib formulations for dispersive and inhalation administration, including salts thereof, indolone derivatives or salts thereof, and in fixed dose combinations with a carrier agent and other active ingredients. The aerosol delivery combination formulation may be administered as an inhalation aerosol over several actuations or by two or more actuations. Each dose may be administered one or more times per day according to a regular or interval daily dosing regimen. Specific formulation parameters of the present invention include the selection of salts complexed with the nintedanib form for the isolated dry powder, as well as particle size distribution and in combination with force control agents to improve aerosol delivery. The methods of the invention comprise therapeutically effective doses of the described invention for the treatment of interstitial lung disease.

The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) Netupitant or salt or hydrate thereof, and (b) Palonosetron or salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet, the method comprising: (i) wet granulating a dry mixture comprising Netupitant or a salt or hydrate thereof, filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising Palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules, (ii) blending the granules with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compressing of the lubricated granules to produce a tablet. The invention further relates to the pharmaceutical composition for use in the treatment and / or prevention of nausea and / or vomiting, preferably in the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetogenic cancer chemotherapy, for example cisplatin cancer chemotherapy.

This disclosure provides methods for treating a condition or disease associated with weight gain that include administration of an apelin receptor agonist alone or in combination with a GLP-1 receptor agonist. Methods for increasing total weight loss in the subject relative to weight loss that would be caused by administration of a pre-determined amount of a GLP- 1 receptor agonist alone are also provided. In some embodiments, the method is for preserving, or maintaining muscle mass, muscle function, and / or muscle strength in a subject undergoing weight loss therapy. Also provided are method of treating diabetes or diabetic obesity. Also provided are method of treating heart failure with preserved ejection fraction. Also provided are pharmaceutical compositions, such as fixed dose combinations, that include an apelin receptor agonist and a GLP-1 receptor agonist. In some embodiments, the pharmaceutical composition is formulated for oral administration.

Described are pharmaceutical compositions in fixed dose combinations containing: a) a dofetilide component; and b) a mexiletine component; wherein the dofetilide component and the mexiletine component are physically separated from each other, along with methods of treating or preventing atrial fibrillation or a symptom associated therewith in a subject in need thereof by administering to the subject such a pharmaceutical composition and methods of preparing such fixed dose combination products.

The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

A method for improving cognitive function in a human suffering from a neurodegenerative cognitive disorder includes introducing a therapeutic amount of quaternary ammonium antimuscarinic compound into a body of a human at a first initial time, introducing a therapeutic amount of a cholinesterase inhibitor into the body of the human at a second initial time, releasing the therapeutic amount of the quaternary ammonium antimuscarinic compound into the body of the human at a first rate, and releasing the therapeutic amount of the cholinesterase inhibitor into the body of the human at a second rate. The first rate is different than the second rate.

Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflorithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.

The present disclosure provides for fixed-dose combination formulations comprising flavoxate or a pharmaceutically acceptable salt thereof and at least one β3-adrenergic receptor agonist, along with methods of making and using the same to treat symptoms associated with prostate, bladder, urinary tract, and pelvic conditions.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

A fixed dose combination formulation drug comprised of three cannabinoids, namely cannabidiol, cannabichromene, and cannabigerol, and of three terpenes, namely alpha-terpinene, bisabolol, and camphene, in an orally available pharmaceutical carrier, for the alleviation of the adverse effects of cancer chemotherapy agents, including adverse effects on the gastrointestinal tract, the chemoreceptor trigger zone, and the peripheral nervous system, and that shows activity adjunctively against ovarian cancer, particularly ovarian cancer that is therapeutically platinum-resistant or platinum-sensitive.

The disclosure relates to fixed dose combinations of the integrin inhibitor bexotegrast ((S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-l,8-naphthyridin-2-yl)butyl)amino)-2- (quinazolin-4-ylamino)butanoic acid) with peroxisome proliferator-activated receptor agonists (PPAR agonists), and methods of treating a subject for a liver fibrotic disease, such as primary sclerosing cholangitis or primary biliary cholangitis, by administration of the fixed dose combinations.

The present invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) netupitant, or a salt or hydrate thereof, and (b) palonosetron, or a salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method for preparing a pharmaceutical composition in the form of a tablet, the method comprises: (i) wet granulating a dry mixture comprising netupitant or a salt or hydrate thereof, a filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules; (ii) blending the particles with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compacting the lubricated particles to produce a tablet. The invention further relates to the use of said pharmaceutical composition for the treatment and / or prevention of nausea and / or vomiting, preferably for the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetically induced cancer chemotherapy, such as cis-platinum cancer chemotherapy.

The present disclosure relates to compositions and methods for treating hormone receptor positive (HR+) cancer with (Z)-endoxifen and a CDK4 / 6 inhibitor, such as abemaciclib. The disclosure is based on the discovery that (Z)-endoxifen and abemaciclib have synergistic effects on reducing tumor growth and proliferation in breast cancer models. The disclosure also provides fixed dose combinations of (Z)-endoxifen and abemaciclib, which offers advantages in terms of convenience and compliance. The compositions and methods are suitable for treating subjects with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer, especially those who are contraindicated for aromatase inhibitor therapy and / or ovarian suppression therapy.

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.

The present disclosure relates to combinations of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of a fixed dose combination product, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and / or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

A pharmaceutical combination. The pharmaceutical combination contains a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic marker thereof, a crystalline form thereof, a hydrate, a solvate, a diastereoisomer or an enantiomer form, and a biguanide hypoglycemic drug. A pharmaceutical composition and a fixed dose combination preparation as well as a preparation method and use of the pharmaceutical composition and the fixed dose combination preparation.

Disclosed is a composition that can be used to treat an immune-mediated inflammatory disease or cancer of a mammalian receptor, wherein the composition comprises a synergistic combination of a cannabis derivative compound and a pharmaceutically acceptable mushroom.

The present application relates to an inhalable liquid composition suitable for nebulization comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide for treating a pulmonary disorder(s). The present application also relates to a process for preparing such a composition comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide.

Provided herein are pharmaceutical compositions comprising obicetrapib, or a pharmaceutically acceptable salt, solvate or co-crystal thereof, including, for example, obicetrapib calcium, obicetrapib calcium which, as used herein, is obicetrapib hemicalcium, and which may, in many embodiments, be amorphous obicetrapib hemicalcium; ezetimibe; a surfactant; and optionally one or more additional pharmaceutically acceptable excipients. Also provided are pharmaceutical dosage forms, including processes for making such pharmaceutical compositions, and methods for using such pharmaceutical compositions in the treatment of subjects including in treatments requiring reduction in LDL cholesterol and / or an increase in HDL cholesterol.

Methods are presented for improving atherosclerotic plaque characteristics in a patient with atherosclerotic cardiovascular disease (ASCVD). The method comprises administering an effective amount of obicetrapib, or pharmaceutically acceptable salt, solvate, or co-crystal thereof, and optionally co-administering an effective amount of ezetimibe, or pharmaceutically acceptable salt or solvate thereof, to the patient. Methods are also provided for reducing coronary artery inflammation in a patient with atherosclerotic cardiovascular disease (ASCVD). The method comprises administering an effective amount of obicetrapib, or pharmaceutically acceptable salt, solvate, or co-crystal thereof, and optionally co-administering an effective amount of ezetimibe, or pharmaceutically acceptable salt of solvate thereof, to the patient. In preferred embodiments, obicetrapib is administered as amorphous obicetrapib hemicalcium. In particularly preferred embodiments, amorphous obicetrapib hemicalcium and ezetimibe are administered daily in a fixed dose combination (FDC) oral dosage form.

A composition useful for treating immune-mediated inflammatory diseases or cancer in mammalian subjects. The composition includes a synergistic combination of a cannabis derived compound, and a medicinal mushroo

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The present disclosure relates to combinations of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of a fixed dose combination product, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The present invention relates to the field of treatment of parasites, in particular to a method of treating subjects suffering from soil transmitted helminths by administering a pharmaceutical composition comprising ivermectin and a benzimidazole carbamate formulated as a fixed-dose combination, a pharmaceutical composition in the form of a fixed-dose combination comprising ivermectin and benzimidazole carbamate, said composition for use in the treatment of subjects suffering from parasites and a method for producing a fixed-dose combination comprising ivermectin and benzimidazole carbamate.